1 Stock Under $65 That You Shouldn't Ignore Leading biopharmaceutical company Gilead Sciences (GILD) reported impressive sales in the last quarter and raised its full-year 2022 guidance. Furthermore, the company’s strategic acquisitions, drug approvals, and research breakthroughs should… Previous Article A Guide to Becoming an Effective Leader: The 6 Traits of Every Successful Leader Next Article Why You Need to Build Sustainability Into Your Business Strategy
